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Abstract 
Background: Prior research suggests that 60-74% of males and 16-45% of females with fragile X 
syndrome (FXS) meet criteria for autism spectrum disorder (ASD) in research settings. However, 
relatively little is known about the rates of clinical diagnoses in FXS and whether such diagnoses are 
consistent with those performed in a research setting using gold standard diagnostic tools. Method: This 
study explored whether boys and girls with FXS met criteria for ASD in a research setting using the 
Autism Diagnostic Observation Schedule (ADOS; Lord et al. 2001) and the Autism Diagnostic 
Interview-Revised (ADI-R; Lord et al. 1994), and then compared these data with the frequency of parent-
reported clinical diagnoses. We also examined child and family characteristics as potential diagnostic 
predictors across settings. Participants included 35 females and 51 males with FXS (mean age: 10 years), 
who were from Eastern and Midwestern regions of the United States. Results: About half of the children 
met criteria for ASD on either the ADOS or ADI-R, with ASD occurring three times more frequently in 
males than females (~75% versus ~25%). In contrast, ~25% of participants of both genders had received a 
clinical diagnosis of ASD. While cognitive and language skills predicted diagnostic outcome on the 
ADOS and ADI-R, these skills did not predict clinical diagnoses. Executive functions predicted clinical 
diagnoses, but not diagnoses per the ADOS or ADI-R. Conclusions: ASD in FXS may be under-
diagnosed in clinical/educational settings, which raises questions regarding access to ASD-related 
services.  
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Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability, and the 
most common known monogenic disability associated with autism spectrum disorder (ASD; Cohen et al. 
2005). FXS occurs in 1 in 2,500 individuals (Hagerman 2008, Fernandez-Carvajal et al. 2009) and is 
caused by a mutation in the Fragile X Mental Retardation 1 (FMR1) gene. This mutation prevents the 
production of Fragile X Mental Retardation Protein (FMRP), a protein that is essential for brain 
development, giving rise to the neurocognitive phenotype that defines FXS (Loesch et al. 2004, Tassone 
et al. 1999). Notably, there is significant overlap in the behavioral phenotypes of FXS and ASD, 
including shared social and communication deficits (Hagerman and Hagerman 2002). While reported 
rates vary according to diagnostic method and participant characteristics (e.g., age, gender), it is estimated 
that 25-50% of males with FXS meet diagnostic criteria for autistic disorder in a research setting, which is 
defined by social and communication impairments, and the presence of restricted/repetitive behaviors 
(American Psychological Association 1994). Rates are much higher when considering the number of 
males who meet diagnostic criteria for ASD (i.e., an umbrella term, including autistic disorder as well as 
milder variants such as pervasive developmental disorder-not otherwise specified, or PDD-NOS). Sixty to 
seventy-four percent of males with FXS meet criteria for ASD in a research setting (Harris et al. 2008, 
Clifford et al. 2007, Rogers et al. 2001). Reported rates in females with FXS are lower than those in 
males, with 13-20% meeting criteria for autistic disorder, and 45% for ASD (Clifford et al. 2007, Hall et 
al. 2008). See Table 1 for detailed review of reported rates of ASD in FXS.  
While several research groups have examined the rate of ASD comorbidity in FXS within a 
research context, much less is known about the rate at which individuals with FXS are diagnosed with 
ASD in real-life clinical or educational settings. Our knowledge of this topic is limited to one report by 
Bailey and colleagues (2008), who found that ~45% of males and ~15% of females were reported to have 
been diagnosed with and/or treated for autism in a large, nationally-representative survey of families of 
individuals with FXS. While these figures are generally consistent with the rates of research-derived 
diagnoses of autistic disorder, they are considerably lower than rates reported for ASD. Thus, questions 
remain regarding clinical ASD diagnostic practices and how these diagnoses might agree with estimates 
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using gold standard diagnostic tools. Better understanding of ASD diagnostic practices in FXS has 
important implications for clinical practice, given that diagnostic classification may dictate the 
type/intensity of services that a child will qualify for in certain medical and educational settings. 
Research strongly suggests that ASD comorbidity has a significant impact on functional 
outcomes for individuals with FXS. Children with FXS and co-occurring ASD present with a behavioral 
phenotype that is distinct from that of FXS without ASD, and which is characterized by more significant 
cognitive impairment (Bailey et al. 2000, Bailey et al. 2001, Clifford et al. 2007, Loesch et al. 2007, 
Dissanayake et al. 2009, Rogers et al. 2001), greater social impairment (Hernandez et al. 2009, Kau et al. 
2004, Budimirovic et al. 2006, Kaufmann et al. 2004, Hessl et al. 2006), poorer adaptive functions 
(Rogers et al. 2001, Kau et al. 2004), increased likelihood for developing secondary medical conditions 
(Garcia-Nonell et al. 2008), and, according to some reports, decreased receptive language skills (Lewis et 
al. 2006, Rogers et al. 2001). Furthermore, it appears that ASD symptoms in FXS remain relatively stable 
over time (Hernandez et al. 2009, Sabaratnam et al. 2003), suggesting that children are not likely to 
“grow out of” autistic behaviors without specialized intervention. Given evidence that individuals with 
FXS and comorbid ASD are at risk for suboptimal outcomes, ASD comorbidity should be a key factor in 
determining the type and intensity of interventions for this population. Further, because individuals with 
FXS and ASD may present with unique phenotypic profiles, it is essential to consider the presence of 
ASD features in studies of behavior, brain, and genetic effects in FXS. 
 Better understanding of the use of ASD diagnostic tools in FXS is also critical for research. It is 
unclear how different diagnostic tools might be better able to tease apart these complex phenotypes of 
FXS, and how the use of different tools might influence study results. For example, in a longitudinal 
study of 56 boys with FXS, Hernandez et al. (2009) found that the Autism Diagnostic Observation 
Schedule (ADOS; Lord et al. 2001) over-identified children with FXS as having ASD as compared to the 
Autism Diagnostic Interview-Revised (ADI-R; Lord et al. 1994) and the Diagnostic and Statistical 
Manual of Mental Health Disorders (DSM-IV; American Psychological Association 1994). On the other 
hand, in a different study of 63 boys, Harris et al. (2008) suggested that the ADI-R over-identified ASD in 
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FXS, presumably because of its focus on behaviors during early childhood, when autistic-like symptoms 
may be most prominent. Clarifying best practices for diagnosing ASD within the context of FXS will 
allow for more efficient and accurate phenotypic characterization, which is a foundational step in 
answering broader questions regarding the role of ASD in biobehavioral pathways of FXS.  
Recently, FXS has been proposed as a genetic model for informing the etiological basis of ASD 
(e.g., Abrahams and Geschwind 2010, Belmonte and Bourgeron 2006, Hagerman et al. 2011). As a 
single-gene disorder that is associated with significant genetic risk to ASD, FXS provides an opportunity 
to link a known genetic mutation with core behavioral and biological features associated with ASD. 
FMR1 interacts with other background genes that are involved in ASD, thereby reducing the genetic 
threshold needed to produce ASD (Bailey et al. 2001, Rogers et al. 2001). A number of molecular-genetic 
studies support this hypothesis with direct evidence indicating that the protein that is encoded by FMR1, 
FMRP, is involved in the regulation of a number of autism susceptibility genes (Iossifov et al. 2012, 
Darnell et al. 2011, Darnell and Klann 2013). For example, a significant proportion of autism candidate 
genes are now understood to interact with FMRP (Darnell and Klann 2013), and a number of proteins that 
are implicated in idiopathic ASD (including SHANK3, CYFIP1, PTEN, and NRXNI) are regulated by 
FMR1-associated mechanisms such as FMRP and components of the mGluR signaling pathway (Bagni et 
al. 2012, Iossifov et al. 2012, Darnell et al. 2011, Darnell and Klann 2013, Hagerman et al. 2010, De 
Rubeis and Bagni 2011). Clarifying the rate at which ASD occurs in FXS (and how diagnostic practices 
impact this estimate) will contribute to our understanding of the coupling between the FMR1 mutation 
and the development of ASD. 
This study examined rates of ASD among boys and girls with FXS by comparing the children’s 
history of clinical diagnoses of ASD with diagnostic assessments conducted using gold standard 
instruments in a controlled research setting. The concordance of ASD status across diagnostic methods 
was examined to inform diagnostic patterns that have implications for clinical and research practices in 
FXS. Finally, potential predictors of ASD diagnoses were examined, in order to shed light on factors that 
might influence the identification of ASD in FXS. 
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Methods 
Participants 
Eighty-six children with FXS participated in the study (51 boys and 35 girls). The average age of 
all participants was 10.77 years (SD = 3.64), with a mean age of 11.75 (SD = 3.11) for boys and 9.38 (SD 
= 3.91) for girls. The children who participated in this study were recruited from a larger, longitudinal 
study of language in FXS (XX). Children were selected for participation from the larger pool if they had 
been administered the Family History Interview (which assesses clinical diagnostic history) and either of 
the gold standard diagnostic tools, all described below. Participants were ascertained through medical 
facilities and parent groups, and through the XX. Recruitment was based in the Eastern and Midwestern 
regions of the United States. As inclusionary criteria for the larger study, all participants were verbal 
(using three-word phrases) and were native speakers of English. See Table 2 for demographic 
characteristics.  
Procedures 
Assessments were administered within the context of the broader research protocol. While all 
child-based measures were administered concurrently, it was not always possible to administer the 
caregiver-report measures (the Family History Interview [Bolton et al., 1994] and the Autism Diagnostic 
Interview-Revised [ADI-R; Lord et al., 1994], described below) concurrently with the child assessments. 
An average of 11 months passed between administration of the Family History Interview and the child 
assessments, and an average of six months between the ADI-R and child assessments. Procedures were 
approved by the Institutional Review Boards of XX. 
ASD Diagnostic Procedures 
Gold standard ASD assessments. Two ASD diagnostic assessments were administered: the 
Autism Diagnostic Interview-Revised (ADI-R; Lord et al. 1994) and the Autism Diagnostic Observation 
Schedule (ADOS; Lord et al. 2001). In the ADI-R, an examiner leads the caregiver through an interview 
designed to elicit descriptions of the child’s social, communicative, and repetitive/restricted/stereotyped 
behaviors. The diagnostic algorithm is based on symptoms exhibited during early childhood (focused on 
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4-5 years of age), and yields a diagnosis of “autism” or “no autism”. In order to meet diagnostic criteria 
for “autism” participants must meet thresholds for four symptom domains: social interaction, 
communication, restricted/repetitive/stereotyped behavior, and onset before three years. The ADI-R was 
coded by examiners who had achieved research reliability per the standards of the instrument developers. 
The second gold standard diagnostic instrument, the ADOS, bases diagnoses on direct 
observation of behaviors during a play-based interaction. All examiners were trained to reliably code the 
ADOS either through training with the developers of the ADOS or through intra-lab reliability, in 
accordance with the standards of the instrument developers. Classification of “autism”, “autism spectrum” 
and “no autism” was determined using the revised ADOS algorithms (Gotham et al. 2007), which 
consider information from all three domains of the autism triad in determining diagnostic status (whereas 
the original algorithms did not take into account restricted/repetitive features). Individuals who met 
diagnostic thresholds for either “autism” or “autism spectrum” were considered “positive” for an ASD 
diagnosis. This strategy was chosen as it is consistent with the DSM-5 diagnostic criteria for ASD, which 
collapse autistic disorder and PDD-NOS into the single category, “autism spectrum disorder” (American 
Psychiatric Association 2013). ADOS diagnostic information was missing for one male, who was unable 
to complete the assessment due to problem behaviors. 
Clinical diagnoses of ASD. Clinical diagnoses of ASD were determined via caregiver report 
within the context of an abbreviated Family History Interview (Bolton et al. 1994), which was most often 
completed by the participant’s mother prior to the ADI-R. Within the context of a broader interview about 
family structure and medical histories, caregivers were asked whether anyone in their family (including 
their child) had a diagnosis of autism or autism spectrum disorder. While the Family History Interview is 
a well-established method for evaluating autism family history, reports are based solely on caregiver 
recollection of whether the child had been evaluation and what the outcome was. Therefore, two 
circumstances might apply to children who were reported to be negative for a clinical diagnosis: (1) the 
child had been evaluated but did not meet criteria for an ASD diagnosis or (2) the child had never been 
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referred/evaluated for ASD diagnostics. Children whose caregivers reported a diagnosis of autism, autism 
spectrum disorder, or PDD-NOS were considered “positive” for a clinical diagnosis of ASD.  
Predictors of ASD Diagnosis 
Cognitive and language ability. Nonverbal cognitive ability was assessed using the Leiter 
International Performance Scale-Revised Brief IQ (Leiter-R; Roid and Miller 1997). Receptive and 
expressive language ability were also measured, with the Peabody Picture Vocabulary Test-III (PPVT; 
Dunn and Dunn 1997) and the Expressive Vocabulary Test (EVT; Williams 1997), respectively. Age 
equivalent scores were computed for each measure from published norms.  
Executive functions. The Behavior Rating Inventory of Executive Function-Preschool Version 
(Brief-P; Gioia et al. 2000) was used as a caregiver-report scale of executive functions such as inhibition, 
shifting emotional control, and planning/organizing. The preschool version was administered as the 
younger items were judged to be more closely aligned with the mental age of the participants. Because a 
number of participants were thus outside of the age range of the normative sample for the Brief-P, raw 
scores of the Global Executive Composite were used in analysis.  
Behavioral and emotional problems. The Child Behavior Checklist-1 ½-5 years (CBCL; 
Achenbach and Rescorla 2000) was completed by the primary caregiver to assess child maladaptive 
behavioral and emotional problems. The total score was examined, which includes a range of symptoms 
such as social problems, anxiety, and destructive behavior. Like the Brief-P, the younger version of the 
CBCL was administered as the items were thought to be more applicable to the functioning level of the 
participants. Raw scores were used, which is recommended by the test publishers (Achenbach and 
Rescorla 2000).  
Socioeconomic factors. Maternal education level (in years) and household income (<39k, 40-79k, 
<80k) were collected using a standard demographic survey. 
Analysis strategy 
Descriptive statistics were used to examine the rates of ASD diagnoses. Gender differences in the 
rates of ASD were tested using Fisher’s exact test. The concordance of clinical and gold standard 
AUTISM IN FRAGILE X SYNDROME                                        8 
 
 
 
diagnoses was determined by calculating point-to-point “agreement” for each participant. The term 
“agreement” is used throughout to describe the concordance of the various ASD diagnostic methods. 
However, it should be noted that the Family History Interview does not include extensive clinical 
evaluation. As such, reports of clinical diagnostic status were based solely on caregiver recollection of 
whether children had been evaluated and what the outcome was. Therefore, using the Family History 
Interview we were unable to determine whether a “negative” agreement might in some cases reflect 
children never having been evaluated for ASD. Finally, the contribution of the predictor variables to 
diagnostic outcomes was examined with a series of binary logistic regression models. Because children 
who are older may have had more opportunities to have been evaluated for ASD (Bailey et al. 2008), 
chronological age was covaried in the models to facilitate comparison across genders.  
Results 
Rates of ASD Across Diagnostic Methods 
Using the stringent criterion of meeting cut-off on both the ADI-R and the ADOS, 43.5% of 
participants met criteria for ASD overall. Sixty percent of the males met the stringent criteria, and 14.3% 
of the females (see Figure 1). Using the ADI-R only, just over half of the sample (53.5%) met criteria for 
ASD. Among the males, 74.5% met ADI-R cut-offs, while 22.9% of the females did. Slightly more 
participants (56.5%) scored above ADOS diagnostic cut-offs. Seventy-eight percent of the males and 
25.7% of the females met ADOS criteria. Significant gender effects were detected for the rate of 
diagnoses per the ADOS, ADI-R, and ADI-R+ADOS (ps < .001), with more males diagnosed with ASD 
than females. Twenty-five percent of children (25.5% of males and 22.9% of females) had been 
diagnosed with ASD clinically, and no gender effects were detected (p = .494). 
Agreement Among Diagnostic Methods  
Agreement between clinical diagnosis and the ADI-R+ADOS. Using stringent research 
classification (meeting cut-offs for both the ADI-R and the ADOS), the agreement with clinical diagnosis 
was 68% in the full sample. More individuals were identified as positive for ASD on the ADI-R+ADOS 
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than by clinical diagnosis. Sixty percent of individuals who met criteria on the ADI-R+ADOS did not 
have a clinical diagnosis, whereas 30% who had a clinical diagnosis did not meet ADI-R+ADOS criteria. 
For males, the ADI-R+ADOS classification was concordant with clinical diagnoses 56% of the 
time. Of the 30 males who were positive on the ADI-R+ADOS, 66.6% had not received a clinical 
diagnosis. Two males had received a clinical diagnosis without also meeting diagnostic criteria on the 
ADI-R+ADOS. For females, agreement was 85.7%. One of the five females who were identified with the 
ADI-R+ADOS did not have clinical diagnoses (20%), and 50% of the females had a clinical diagnosis yet 
did not meet thresholds on both the ADI-R and ADOS.  
Agreement between clinical diagnosis and the ADI-R. Agreement between the ADI-R and 
caregiver reports of clinical diagnoses was 68.6% overall (see Table 3). More individuals were identified 
as positive on the ADI-R than by clinical diagnosis; 55.6% of the individuals who were identified with 
the ADI-R did not have a clinical diagnosis (whereas 5% of those who had a clinical diagnosis did not 
meet ADI-R thresholds). For males, clinical diagnoses agreed with the ADI-R in 51% of cases, with 
discrepancies related to higher identification with the ADI-R than clinical diagnosis (65.8% of the males 
who were identified with the ADI-R did not have a clinical diagnosis). For females, overall agreement 
was 94.3%; 12.5% were positive on the ADI-R but not clinically and 12.5% had a clinical diagnosis yet 
did not meet ADI-R criteria.  
Agreement between clinical diagnosis and the ADOS. Within the full sample, 52.9% of the 
caregiver-reported clinical diagnoses agreed with ADOS classification. Agreement was lower among 
males than females  (40% versus 74.3%, respectively). Diagnostic disagreements were most often related 
to higher identification rates with the ADOS (70.8% of children who met ADOS criteria did not have a 
clinical diagnosis). Among males, 74.4% met criteria on the ADOS but did not have a clinical diagnosis, 
whereas 16% had a clinical diagnosis but did not reach ADOS thresholds. Of the females, 55.6% were 
positive on the ADOS yet did not have a clinical diagnosis. Fifty percent of the females who had received 
a clinical diagnosis did not meet ASD criteria (see Table 3).  
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Agreement between ADI-R and ADOS. The ADI-R and ADOS agreed 76.5% of the time in the 
full sample. Twenty-two percent of children who were positive on the ADI-R were not identified with the 
ADOS, and 27.1% of those who were positive on the ADOS were negative on the ADI-R. ADOS and 
ADI-R agreement was lower for males (68%) than females (80%). Discrepancies did not appear to be 
related to one instrument over-identifying ASD in comparison to the other; see Table 4).   
Predictors of ASD Diagnosis 
Cognitive and language predictors. In the full sample, nonverbal mental age, receptive 
vocabulary, and expressive vocabulary were significant predictors of ADI-R and ADOS diagnoses (with 
the odds of having ASD decreasing as each of these skills increased). Mental age, receptive vocabulary, 
and expressive vocabulary did not predict clinical diagnoses (see Table 5). No significant predictors of 
ASD emerged among the subgroups of males or females, although there was a trend for nonverbal mental 
age as a predictor of ADI-R status among females (OR= .47, p = .088).  
Behavioral predictors. Executive functions and behavioral/emotional control were not significant 
predictors of diagnostic outcome on the ADOS or ADI-R; however, there were trends for increased 
likelihood of a diagnosis on the ADI-R as behavioral/emotional problems increased, and for increased 
likelihood of ADOS diagnosis with greater executive impairment (see Table 6). Executive function 
significantly predicted caregiver-reported clinical diagnoses, with increased odds of having a diagnosis 
with greater executive impairment after controlling for age (OR = 1.04, p = .013). In the gender 
subgroups, executive function significantly predicted clinical diagnoses in males but not females. 
Behavioral/emotional problems did not significantly predict ADOS or ADI-R outcomes, although a trend 
was detected for increased odds of a clinical diagnosis with more significant behavioral/emotional 
difficulties (OR = 1.02, p = .062). 
Socioeconomic predictors. Neither maternal education level nor household income significantly 
predicted ADI-R, ADOS or clinical diagnoses. There was, however, a trend for decreased likelihood of 
diagnosis per the ADOS as income level increased from the <40k to 40-79k income bracket (OR = 11.37, 
p = .063).  
AUTISM IN FRAGILE X SYNDROME                                        11 
 
 
 
Discussion 
This study examined the agreement between ASD diagnoses derived from clinical and research 
settings in boys and girls with FXS and examined potential correlates of ASD diagnoses. While high 
agreement was observed between the ADOS and ADI-R administered as part of a research protocol, there 
was poor agreement between these measures and caregiver-reported clinical diagnoses; over half of the 
children who met diagnostic criteria for ASD in the research protocol were not identified as having ASD 
clinically.  
Approximately 65% of the boys and 20% of the girls who met criteria for ASD as part of the 
research evaluation had not been previously identified as having ASD in other settings, according to 
caregiver report. This suggests that a significant proportion of children with FXS who would meet 
diagnostic criteria for ASD are not identified clinically (although it is unknown whether this is due to 
under-referral of children with FXS for ASD diagnostics versus false negatives in clinical evaluation). 
Boys in particular were likely to meet criteria for ASD in the research setting despite being negative for a 
clinical diagnosis, suggesting that under-diagnosis may be common among boys with FXS. While more 
research is needed to investigate this finding, it is possible that ASD comorbidity is more likely to be 
overlooked in boys with FXS, who are generally more affected than girls and may be more likely to 
receive services under a diagnosis of “intellectual disability” as opposed to “ASD”. Because girls with 
FXS are less affected, the presentation of ASD among girls may also stand out more clearly, drawing the 
attention of caregivers and health/educational professionals. 
Under-diagnosis of ASD in individuals with FXS has important implications for services, given 
that in many settings diagnostic classification precedes (and often dictates) the type/intensity of services. 
Because diagnostic classification serves as a guide for health practitioners and educators, professionals 
who are aware of ASD comorbidity might be better able to tailor treatment towards ASD-related 
symptoms. For example, health care providers who are aware of ASD comorbidity might be more 
watchful of secondary medical conditions that are more common in FXS with co-occurring ASD, such as 
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seizures (Garcia-Nonell et al. 2008). Overall, more accurate diagnostic information can only assist in 
making informed medical/educational decisions. 
While findings support a clear trend of higher identification with the ADOS/ADI-R as compared 
to clinical diagnoses, there was a subset of children who were identified clinically but did not meet 
criteria for ASD in the research setting. This pattern appeared to be specific to the ADOS, which failed to 
identify 30% of the children with a clinical ASD diagnosis, rather than the ADI-R (which missed less 
than 1% of children). In particular, the ADOS appeared to be less sensitive in identifying ASD in females, 
missing half of the females who had received a clinical diagnosis. Additional research is needed to 
determine the cause of this pattern. It is possible that females with FXS are adept at compensating for 
social difficulties during short-lived interactions such as the ADOS and therefore do not show sufficient 
features to meet diagnostic criteria on this measure, whereas clinical diagnoses and the ADI-R are able to 
incorporate more comprehensive information regarding the child’s behaviors in everyday settings.  
In attempts to inform potential reasons for under-diagnosis, this study explored factors that may 
make an individual more likely to be referred, evaluated, and eventually diagnosed with ASD. Contrary to 
expectations, we found that mental age and language skills did not predict clinical diagnoses (although 
they did predict ADOS/ADI-R diagnoses, as would be expected given that ASD comorbidity in FXS is 
associated with greater impairment). Perhaps health professionals expect language and cognitive delays as 
a part of FXS, and therefore are likely to overlook red flags for ASD when a child is also struggling with 
language and cognitive skills. Rather, clinical diagnoses became more likely as children showed greater 
deficits in executive functions. This suggests that regulatory management deficits (e.g., impulsivity, 
cognitive inflexibility) may be salient features that prompt health professionals to assess for ASD. 
Surprisingly, socioeconomic variables did not predict clinical diagnoses (families with more resources 
would be expected to have better access to services). Perhaps this study was under-powered to detect 
effects; or, the income categories may have been too broad to capture subtle trends. Other factors not 
measured in this study, such as personal beliefs about the nature of ASD in FXS, may also have a 
substantial influence on diagnostic patterns. Anecdotally, many caregivers commented during the clinical 
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interview that although their child shows symptoms that are consistent with ASD, their child does not 
have ASD because such symptoms are caused by FXS. The question of whether ASD within FXS 
represents “true” autism is a question that researchers, clinicians, and families alike have grappled with, 
and one that has immense implications for diagnosis and intervention. Stakeholders who hold the view 
that ASD symptoms are not independent from FXS may be less likely to pursue ASD-related services.  
Findings were generally consistent with prior reports. In females, this study detected rates of 20-
25% across the ADOS and ADI-R, which is consistent with prior estimates ranging from 3-45% (Hall et 
al., 2008, Clifford et al., 2007; McDuffie et al., 2010). For males, the rates detected with the ADOS were 
comparable to existing studies, whereas the rates detected with the ADI-R were elevated, with 
approximately three-fourths of the boys meeting diagnostic thresholds on the ADI-R, in contrast to 45-
50% in prior research (Harris et al., 2008; Rogers et. al. 2001). Differences in participant characteristics 
may account for discrepant findings; this study excluded nonverbal individuals, which may have led to 
the inclusion of a subgroup of children who were more likely to meet ADI-R diagnostic thresholds. In 
fact, Kaufmann et al. (2004) found that better expressive language skills predicted more severe ADI-R 
scores in boys with FXS. A report by McDuffie et al. (2010) also examined a group of verbal boys with 
FXS and found that 63% met diagnostic criteria on the ADI-R.  
In general, the ADOS and the ADI-R yielded comparable rates of ASD. Within individual 
participants, agreement between the ADOS and ADI-R was high (~70% for boys and ~80% for girls), 
supporting their use with individuals with FXS. It is unclear how the ADOS/ADI-R agreement detected in 
this study compares with that of prior research, as no studies to our knowledge have reported 
concordance/discordance of the two measures in FXS. That is, prior studies have not reported the 
diagnostic agreement across tools at the participant level, although a number of studies have compared 
overall diagnostic rates per instrument. Even if both instruments detected similar group rates of ASD, this 
does not necessarily indicate that both tools identified the same participants as having ASD.   
While this study provides a starting point for understanding ASD diagnostic practices in FXS, it 
is still unclear why ASD in FXS appears to be under-diagnosed (e.g., whether the low rates of clinical 
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diagnoses were caused by breakdowns in the referral process versus false-negatives in clinical 
evaluation). As noted previously, the clinical diagnoses did not take into account whether participants had 
been evaluated for ASD--it is possible that some children were simply never referred for diagnostic 
evaluation. Along these lines, clinical diagnoses in this study reflect whether caregivers believed that their 
child had ASD, disregarding the setting from which the child’s diagnosis was received. Future studies 
investigating the sources of clinical diagnoses (medical, educational, research, or otherwise) would be 
invaluable in understanding diagnostic practices in FXS. Nonetheless, caregiver beliefs about their child’s 
ASD status are likely to be clinically meaningful (regardless of the source of the diagnosis), as caregivers 
who believe that their child has ASD may seek out services that differ in type or intensity. Currently, it is 
unknown whether knowledge of ASD-status leads to improved educational and medical outcomes for 
children with FXS. Research investigating the functional implications of clinical ASD diagnoses in FXS 
is needed to understand the potential consequences of clinical under-diagnosis of ASD.  
A limitation of this study is that only verbal individuals with FXS were studied, which might 
limit generalizability. Findings should also be replicated in different regions of the US and other 
countries, where diagnostic practices may vary. This study is also limited to examination of a single time 
point and cannot account for potential changes in the presentation of ASD across the lifespan. Finally, this 
study operated under the assumption that the ADOS and ADI-R represented the participant’s “true” 
diagnostic classification. Although these tools are widely used with high sensitivity and specificity, they 
are not comprehensive and should be used within the context of a broader clinical assessment. 
In conclusion, this study identified rates of ASD comorbidity in FXS at about 75% for males and 
25% for females, using gold-standard diagnostic tools. Strikingly, a significant proportion of children 
with FXS who were identified as having ASD in the research setting had not been identified clinically. 
Results may have implications both for clinical practice and research, in that defining clinically distinct 
groups of individuals with FXS allows for tailored intervention and contributes to the identification of 
ASD-associated pathways that become disrupted in the presence of the FMR1 mutation.   
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Table 1. Reported Rates of ASD among Individuals with FXS 
Authors (Year) Sample 
characteristics 
Diagnostic procedures Detected rates of Autism 
Bailey, Raspa, 
Olmsted, & Holiday 
(2008) 
976 males; 259 
females (national 
survey) 
 
6-30+ years (M age 
not reported) 
Caregivers asked: “Has this 
child ever been diagnosed or 
treated by a medical 
professional for any of the 
following conditions… 
autism?” 
Males: 46%  
Females: 16%  
Clifford, 
Dissanayake, Bui, 
Huggins, Taylor, & 
Loesch (2007) 
 
33 males; 31 
females 
(ascertained via 
clinical referrals) 
 
5-60 years (M 23.2) 
Participants who scored above 
SCQ thresholds were 
administered the ADI-R & 
ADOS  
Males: 36% on ADI-R; 67% on ADOS 
for autism/spectrum; 27% on ADI-R+ 
ADOS autism/spectrum 
Females: 3% on ADI-R; 13% on 
ADOS for autism/spectrum; 13% on 
ADI-R+ ADOS autism/spectrum 
Garcia-Nonell, 
Ratera, Harris, 
Hessl, Ono, et al. 
(2008) 
90 males 
 
3-25 years (M ~8) 
ADOS, DSM-IV 63% on ADOS for autism/spectrum + 
DSM-IV for autism or PDD-NOS 
Hall, Lightbody, & 
Reiss (2008) 
31 males; 29 
females 
 
5-20 years (M ~13) 
ADOS Males: 74% for autism/spectrum 
Females: 45% for autism/spectrum  
Harris, Hessl, 
Bacalman, Goodlin-
Jones, Ferranti, et al. 
(2008) 
63 males 
 
2-19 years (M 7.9) 
ADI-R, DSM-IV & ADOS  49% on ADI-R; 49% on ADOS for 
autism/spectrum; 35% on DSM-IV for 
autism; 59% on DSM-IV for PDD-
NOS; 27% on ADI-R+DSM-
IV+ADOS autism/spectrum 
Hernandez, 
Feinberg, Vaurio, 
Passanante, 
Thompson, et al. 
(2009) 
56 males 
 
Age range not 
reported (M 4.7 
years  
ADI-R, DSM-IV 43% on ADI-R+DSM-IV 
Rogers, Wehner, & 
Hagerman (2001) 
23 males; 1 female 
(ascertained via 
ADOS, DSM-IV, & ADI-R 
(used reduced cut-off scores 
46% on ADI-R; 33% on ADI-R+ 
DSM-IV+ ADOS autism/spectrum 
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clinical referrals) 
 
2-4 years (M 2.9) 
for the ADI-R repetitive 
behavior domain) 
Note: ADOS rates are reported for children who met criteria for either “autism” or “autism spectrum”. ADI-R rates 
report the percentage of children who met criteria of “autism” (the ADI-R does not provide diagnostic cut-offs for 
“autism spectrum”). ADOS=Autism Diagnostic Observation Scale; ADI-R=Autism Diagnostic Interview- Revised; 
SCQ=Social Communication Questionnaire; DSM-IV=American Psychiatric Association Diagnostic and Statistical 
Manual- 4th Edition; PDD-NOS=Pervasive developmental disorder-not otherwise specified.  
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Table 2. Participant Characteristics 
 
 
Full sample 
(N = 86) 
Males 
(n = 51) 
Females 
(n = 35) 
Age in years 
M (SD) 
Range 
 
10.77 (3.64) 
4.23-17.90 
 
11.75 (3.11) 
6.47-17.90 
 
9.38 (3.91) 
4.23-15.87 
Mental age  
M (SD) 
Range 
 
5.79 (1.90) 
3.50-14.92 
 
5.11 (0.60) 
3.50-6.67 
 
6.77 (2.60) 
3.92-6.77 
FSIQ 
M (SD) 
Range 
 
64.22 (24.05) 
36.00-124.00 
 
49.94 (12.99) 
36.00-79.00 
 
84.63 (21.25) 
38.00-124.00 
Maternal education 
M (SD) 
 
15.72 (2.06) 
 
15.79 (2.13) 
 
15.62 (2.00) 
Race 
White 
African American 
Other 
 
79.1% 
5.8% 
9.3% 
 
84.3% 
3.9% 
7.8% 
 
71.4% 
8.6% 
11.4% 
Household Income 
<20k 
40-79k 
>80k 
 
7.7% 
20.5% 
70.8% 
 
5.7% 
22.9% 
71.4% 
 
7.7% 
21.5% 
70.8% 
 
  
AUTISM IN FRAGILE X SYNDROME                                        18 
 
 
 
Table 3. Number of Children Identified as Positive or Negative for ASD via Gold Standard Diagnostic 
Tools in Comparison to Clinical Diagnoses 
 
 Clinical Diagnosis 
 Full Sample  Males  Females 
 Pos.  Neg. Total  Pos. Neg. Total  Pos. Neg.  Total 
ADI-R+ADOS  
Positive 
Negative 
 
14 
6 
 
21 
44 
 
35 
50 
  
10 
2 
 
20 
18 
 
30 
20 
  
4 
4 
 
1 
26 
 
5 
30 
Total 20 65 85  12 38 50  8 27 35 
ADI-R 
Positive 
Negative 
 
20 
1 
 
26 
39 
 
46 
40 
  
13 
0 
 
25 
13 
 
38 
13 
  
7 
1 
 
1 
26 
 
8 
27 
Total 21 65 86  13 38 51  8 27 35 
ADOS  
Positive 
Negative 
 
14 
6 
 
34 
31 
 
48 
37 
  
10 
2 
 
29 
9 
 
39 
11 
  
4 
4 
 
5 
22 
 
9 
26 
Total 20 65 85  12 38 50  8 27 35 
Note: ADI-R=Autism Diagnostic Interview-Revised. ADOS=Autism Diagnostic Observation 
Schedule 
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Table 4. Number of Individuals Identified as Positive or Negative for ASD According to the ADI-R and 
ADOS 
 
 ADI-R 
 Full Sample  Males  Females 
 
 
 
ADOS 
 Pos. Neg. Total  Pos.  Neg. Total  Pos. Neg. Total 
Positive  
35 
 
13 
 
48 
 
 
30 
 
9 
 
39 
 
 
5 
 
4 
 
9 
Negative 10 27 37  7 4 11  3 23 26 
Total 45 40 85  37 13 50  8 27 35 
Note: ADI-R=Autism Diagnostic Interview- Revised; ADOS=Autism Diagnostic Observation Schedule 
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Table 5. Regression Coefficients Showing Cognitive and Language Factors as Predictors of ASD 
Classification 
 
 Leiter-R  PPVT  EVT 
 B (SE) OR (95% 
CI) 
 B (SE) OR (95% 
CI) 
 B (SE) OR (95% 
CI) 
ADI-R 
Full Sample 
Males 
Females 
 
-1.03 
(0.32)** 
-0.96 
(0.63) 
-0.76 
(0.44) † 
 
0.36 (0.19-
0.67) 
0.38 (0.11-
1.32) 
0.47 (0.20-
1.12) 
  
-0.42 
(0.13)** 
-0.26 (0.25) 
-0.21 (0.22) 
 
0.66 (0.50-
0.86) 
0.77 (0.48-
1.25) 
0.81 (0.53-
1.24) 
  
-0.44 
(0.14)** 
-0.12 (0.25) 
-0.48 (0.32) 
 
0.64 (0.49-
.847) 
0.99 (0.62-
1.58) 
0.62 (0.33-
1.14) 
ADOS 
Full Sample 
Males 
Females 
 
-0.77 
(0.24)** 
-0.82 
(0.66) 
-0.43 
(0.28) 
 
0.46 (0.28-
0.74) 
0.44 (0.12-
1.61) 
0.65 (0.38-
1.12) 
  
-0.40 
(0.13)** 
-0.12 (0.27) 
-0.24 (0.19) 
 
0.67 (0.52-
0.87) 
0.89 (0.52-
1.50) 
0.79 (0.54-
1.15) 
  
-0.38 
(0.13)** 
-0.11 (0.26) 
-0.16 (0.18) 
 
0.69 (0.53-
0.89) 
0.89 (0.54-
1.47) 
0.86 (0.61-
1.21) 
Clinical 
Diagnosis 
Full Sample 
Males 
Females 
 
-0.29 
(0.23) 
-0.12 
(0.60) 
-0.55 
(0.36) 
 
0.75 (0.47-
1.18) 
0.89 (0.27-
2.89) 
0.58 (0.28-
1.18) 
  
-1.00 (0.13) 
-0.23 (0.25) 
-0.09 (0.19) 
 
0.91 (0.71-
1.16) 
0.79 (0.49-
1.29) 
0.92 (0.63-
1.33) 
  
-0.09 (0.12) 
0.11 (0.24) 
-0.30 (0.26) 
 
0.91 (0.72-
1.15) 
1.12 (0.70-
1.79) 
0.74 (0.44-
1.23) 
Note: **p < .01, †p < .09. All models adjusted for chronological age. ADI-R=Autism Diagnostic 
Interview-Revised; ADOS=Autism Diagnostic Observation Schedule; PPVT=Peabody Picture 
Vocabulary Test; EVT=Expressive Vocabulary Test; Leiter-R=Leiter International Performance 
Scale-Revised. 
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Table 6. Regression Coefficients Showing Executive Function and Behavioral Control as Predictors of 
ASD Classification 
 
 Brief-P Global Executive 
Composite  
 
CBCL Total Score 
 B (SE) OR (95% CI)  B (SE) OR (95% CI) 
ADI-R 
Full Sample 
Males 
Females 
 
0.01 (0.01) 
0.01 (0.01) 
0.02 (0.02) 
 
1.01 (0.99-1.03) 
1.01 (0.98-1.03) 
1.02 (0.98-1.06) 
  
0.02 (0.01)  
0.02 (0.19) 
0.02 (0.02) 
 
1.02 (1.00-1.05) 
1.02 (0.99-1.06) 
1.02 (0.98-1.07) 
ADOS 
Full Sample 
Males 
Females 
 
0.02 (0.01) † 
0.02 (0.02) 
0.02 (0.02) 
 
1.02 (1.00-1.04) 
1.02 (0.99-1.05) 
1.02 (0.98-1.06) 
  
0.01 (0.01) 
-0.01 (0.02) 
0.03 (0.02) 
 
1.01 (0.99-1.04) 
1.00 (0.96-1.03) 
1.03 (0.99-1.07) 
Clinical Diagnosis 
Full Sample 
Males 
Females 
 
0.02 (0.09)* 
0.05 (0.02)* 
0.02 (0.02) 
 
1.04 (1.01-1.07) 
1.05 (1.01-1.10) 
1.02 (0.98-1.07) 
  
0.02 (0.01) † 
0.02 (0.02) 
0.02 (0.02) 
 
1.02 (1.00-1.05) 
1.02 (0.99-1.06) 
1.02 (0.98-1.07) 
Note: *p < .05, †p < .09. All models adjusted for chronological age. BRIEF-P= Behavior 
Rating Inventory of Executive Function- Preschool Version; CBCL=Child Behavior 
Checklist; ADI-R= Autism Diagnostic Interview-Revised; ADOS=Autism Diagnostic 
Observation Schedule;  
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Figure 1. Percent of Children Meeting Criteria for ASD 
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